A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price Momentum [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Why Royalty Pharma (RPRX) Is Drawing Investor Attention Now Royalty Pharma (RPRX) is back on investor radars after a recent move in its share price, prompting a closer look at how its royalty driven model and current financial profile align with different portfolio goals. See our latest analysis for Royalty Pharma. At a share price of $49.38, Royalty Pharma has seen a 21.21% 90 day share price return and a 55.36% 1 year total shareholder return. This indicates that momentum has been building recently as investors reassess its royalty portfolio and cash flow profile. If you are comparing Royalty Pharma with other healthcare names using AI, it can be helpful to scan a broader set of opportunities through 33 healthcare AI stocks With Royalty Pharma trading at $49.38, an intrinsic discount estimate of 73.82% and a small gap to the average analyst target of $52.44, investors may wonder whether there is real upside left or whether the market already reflects future growth. Most
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Biogen (BIIB) Q4 2024 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios (AGIO) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationGlobeNewswire
- Royalty Pharma (RPRX) had its "buy" rating reaffirmed by UBS Group AG.MarketBeat
- Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
RPRX
Sec Filings
- 4/13/26 - Form 8-K
- 4/10/26 - Form ARS
- 4/10/26 - Form DEFA14A
- RPRX's page on the SEC website